Galderma has launched Restylane Defyne™ and Restylane Refyne™, the first Optimal Balance Technology (OBT™) hyaluronic acid injectables approved in Japan.
The products are designed for injection into the mid-to-deep dermis to correct moderate to severe facial wrinkles and folds and are now commercially available across the Japanese market.
The new launches expand Galderma’s Restylane portfolio in Japan to four products, complementing existing NASHA®-powered injectables Restylane Classyc™ and Restylane Lyft™. The broader portfolio enables clinicians to address a wider spectrum of patient needs, from soft, flexible gels for fine lines to firmer formulations for deeper folds and contouring.
Restylane Defyne and Refyne leverage OBT technology, which provides a unique combination of flexibility and support to move naturally with facial expressions while maintaining shape and lift. Restylane Refyne is tailored for delicate, highly expressive areas, while Defyne is suitable for deeper folds and areas such as the jawline. Clinical studies in Japan involving over 300 subjects demonstrated meaningful improvements in wrinkle severity for up to 12 months, with most patients reporting at least a one-grade improvement in self-assessed outcomes within six weeks.
The introduction of these products in Japan aligns the market more closely with global Restylane offerings and strengthens Galderma’s presence in the aesthetics sector across the Japan & Asia Pacific (JPAC) region.
The company positions the launch as part of its long-term strategy to provide healthcare professionals with advanced tools for natural-looking, expressive results and to meet growing aesthetic care needs.
With over 30 years of innovation and more than 77 million treatments worldwide, Restylane continues to address significant aesthetic trends, including facial harmony restoration after weight loss, menopause-related skin changes, and age-related concerns.
Also Read